Member Info for lostinspace69

https://www.gov.uk/government/news/new-saliva-test-for-coronavirus-piloted-in-southampton

In addition to the new application of using saliva from Optigene being piloted in Southampton, we are currently exploring the potential of other no-swab saliva-based coronavirus tests with companies, including Chronomics, Avacta, MAP Science and Oxford Nanoimaging (ONI).

So, not just Optigene being trialed at Southampton.

How can ODX be "much closer than us" to releasing their Anrigen based LFT, when we had a 2 month head start on them??

FD - having a great weekend and hope you are too. GGP is a once in a lifetime investment. Congrats to all long term holders.

I don't have 8 million tickets "pal". I have 13m.

TT - agreed, I doubt it would be retrospective. I can also see them aligning GCT with Income tax and re-introducing taper relief to reward long term holders.

Hey Speedy, I started buying stocks when I was 18 and I’ve made some big mistakes over the years but also learnt a lot too. I’m 50 now and a lot less impetuous. I’m happy to take my time. There’s no rush. I do my research, take my position and hold, for as long as it takes. After I sold my first business, I invested about £250k into Apple back in 2007/2008 and recently sold out there. The journey should be all part of the fun. I never stress about stocks I hold. I run my profits and cut losses. I always consider risk and potential rewards. For me the risk reward ratio on GGP is compelling. So I will hold. GLA

I can see them capping the lifetime limit for ISA. I hold 8.7m of my GGP shares in an ISA with a 2.83p average, so I’m pretty stoked about that!

Lol Speedy .... yes, GGP is more than a dabble for sure. What I meant was that I will always invest in stocks, because to me it’s more of a hobby and something I enjoy. I enjoy the process of researching too. GGP is currently my biggest holding, followed by Avacta. Both very exciting stocks to own.

Holding 13m shares bought between 2p and 8.5p. I see no reason to sell as can’t think of anywhere better to put my money right now. This stock has a lot further to run. My other main holdings are Avacta, SNG and 4D Pharma. I will always dabble in stocks, regardless of how much I make. For me, it’s not really about the money anymore.

wow, what a day! congrats to all long term believers

We need to see big OEM and Public Cloud contracts with meaningful revenue contribution. This company has massive potential, yet to be realised. The next 6 months are critical. Come on Blackbird, time to take flight!

I guessed £600-800k. The actual figure is £714k. Decent progress made, but not enough to justify the next leg up.

My thoughts exactly. I think we were all under the impression that clinical validation was well underway. It seems we have a while longer to wait.

very under rated this stock. huge upside potential as the US states come online.

Raleigh, agree the revenue figure is somewhat irrelevant at this stage and I don't think it's helpful to talk it up. My best estimate would be between £600-£800k in the first half, depending on when they recognise the contracted revenue for 2020. More importantly, we need to see the contracted but unrecognised growing and further evidence of the OEM strategy working.

"It seems like a lot of investors are in denial"....correction, "a few ill informed investors are in denial".

My point was simply that some posters on here choose to be in complete denial and rather than accepting Mologic has a 10 minute saliva test (which I accept might be rubbish and might not), they just completely deny it's existence and instead choose to stick their head in the sand.

I am heavily invested here, so I want nothing more than for Avacta to be the gold standard test that makes global news. At the same time, I do try to keep an open mind to the possibility of competitors emerging.

It seems like a lot of investors are in denial. The test being trialed at Heathrow is a saliva based ANTIGEN test with results in 10 minutes. This test has nothing to do with the ANTIBODY test from the same company. More competitors will surface over the coming days and weeks. Anyone who thought we would have the market to ourselves is a fool. Luckily the size of the market is going to be huge, so plenty of room for several players. But don't deny the existence of another Antigen saliva test. It's being trialed at Heathrow, it isn't Avacta and that's a fact.

Yes, I am only aware of Blue Prism. They will be taken out within 12 months - my bet would be IBM, HP, or one of the US RPA companies

Assume this Abbott test is the reason for the share price decline today? Market got spooked. Are we too late? I don't think so.

Robotic process automation software startup UiPath landed $225 million in a Series E round of funding, bringing its valuation to $10.2 billion.

https://news.crunchbase.com/news/uipath-raises-225m-series-e/

"Gupta notes that UiPath could also be looking at strategic acquisitions in the months ahead to fill in holes in the product roadmap more rapidly"

February 19, 2020 – UiPath, the leading enterprise Robotic Process Automation (RPA) software company, announced today that it closed December 2019 with $360 million in Annual Recurring Revenue (ARR), with net new ARR in the fourth quarter exceeding $60 million.

Blue Prism achieved £100m revenues last year with 98% recurring revenue. In the first 6 months of the current year, they delivered 70% growth to £68.5m with 98% recurring. Should deliver min £170m revenues, almost all recurring. That equates to around $220m dollars. UiPath achieved $360m and in July this year raised $225m at a valuation of $10.2b. So if Blue Prism achieves $220m revenues this year, then based on a similar metric for valuation, we would get to a valuation of circa $6b or £4.7b. Current market cap is £1.3b, so it's not difficult to argue that this company is significantly undervalued compared the wider RPA market.

I would hazard a guess that Blue Prism will be snapped up within 9-12 months and the price paid will be at least double what it is today.